Daily Stock Analysis, ALDR, Alder Biopharmaceuticals Inc, priceseries

Alder Biopharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
9.23
Close
9.75
High
9.77
Low
9.12
Previous Close
9.24
Daily Price Gain
0.51
YTD High
15.17
YTD High Date
Jan 31, 2019
YTD Low
8.39
YTD Low Date
Sep 9, 2019
YTD Price Change
-1.17
YTD Gain
-10.71%
52 Week High
18.95
52 Week High Date
Sep 13, 2018
52 Week Low
8.39
52 Week Low Date
Sep 9, 2019
52 Week Price Change
-8.45
52 Week Gain
-46.43%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 3. 2017
21.30
Feb 16. 2017
23.56
9 Trading Days
10.60%
Link
LONG
Sep 12. 2017
9.90
Oct 16. 2017
12.34
24 Trading Days
24.63%
Link
LONG
Dec 29. 2017
11.45
Jan 22. 2018
16.30
14 Trading Days
42.38%
Link
LONG
Jul 5. 2018
16.85
Jul 19. 2018
18.35
10 Trading Days
8.88%
Link
LONG
Jan 11. 2019
10.83
Jan 29. 2019
11.94
11 Trading Days
10.25%
Link
Company Information
Stock Symbol
ALDR
Exchange
NasdaqGM
Company URL
http://www.alderbio.com
Company Phone
425-205-2900
CEO
Randall C. Schatzman
Headquarters
Washington
Business Address
11804 NORTH CREEK PARKWAY SOUTH, BOTHELL, WA 98011
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001423824
About

Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers, develops, and commercializes various therapeutic antibodies. Its pipeline includes ALD403, Clazakizumab and ALD1613. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA.

Description

Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes therapeutic antibodies in the United States, Australia, and Ireland. The company's lead product candidate includes ALD403, an antibody, which is in Phase II clinical trial to target calcitonin gene-related peptide for the prevention of migraine. It also develops ALD1910, a genetically engineered monoclonal antibody that is in preclinical study for the treatment of migraine; and Clazakizumab, an antibody, which has been completed Phase IIb clinical trial that inhibits the pro-inflammatory cytokine interleukin-6 for the treatment of rheumatoid and psoriatic arthritis. In addition, the company has preclinical programs in the discovery phase for various indications. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.